

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant:	Watkins, Jeffrey D.	Group Art Unit:	1644
Serial No.:	10/553,938	Examiner:	Ron Schwadron, Ph.D.
Application Date:	October 21, 2005	Confirmation No.:	8652
For:	CD20 Binding Molecules		
Docket No.:	X-16760A		

RESPONSE TO NOTICE TO COMPLY

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply dated February 17, 2011 (hereinafter, the "Notice to Comply"), Applicants submit herewith a corrected Annotated Drawing as required by the Examiner. A copy of the Notice to Comply is attached following the corrected Annotated Drawing.

Any fees associated with this response may be charged to Eli Lilly Deposit Account No. 05-0840.

In the Notice to Comply, the Examiner indicated, that "[t]he annotated sheet for Figure 11 (previously Figure 15) recites 'In house Rituxan' in the figure legend box wherein said change from original Figure 15 is not noted as required. In addition, said change is also not found in the corresponding replacement Figure 11 filed 6/1/10."

The Applicants would like to thank the Examiner for identifying this unintended change to their attention. To be clear, the change to "In house Rituxan" in the figure legend box of the annotated sheet for Figure 11 is not a required change from the original Figure 15. Rather, the

substitution of the phrase "In house Rituxan" for the term "C2B8" was unintentional. Therefore, in the enclosed corrected annotated sheet for Figure 11 (previously Figure 15), the phrase "In house Rituxan" has been replaced with "C2B8" so that the corrected annotated sheet now correctly reflects the required changes to original Figure 15. Taken together with the previous submissions of June 1, 2010, and November 29, 2010, the application now contains a complete set of correct annotated sheets for the previously requested amendments to the Drawings. Accordingly, the Applicant respectfully requests entry into the present application the Amendment dated June 1, 2010.

If there are any outstanding issues regarding this response or application, the Examiner is invited to contact the undersigned attorney by telephone at (317) 651-1541 to resolve such issues, so that the claims may be allowed and issued without further delay.

Respectfully submitted,

/Robert L. Sharp/
Robert L. Sharp
Attorney for Applicants
Registration No. 45,609
Phone: (317) 651-1541

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

March 11, 2011

Attachments:

Annotated (marked-up) Sheet

A copy of the Notice to Comply dated February 17, 2011